- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02377492
Paracervical Vasopressin Injection Compared With Intramyometrial Vasopressin in Abdominal Myomectomy
Paracervical Vasopressin Injection Compared With Intramyometrial Vasopressin in Abdominal Myomectomy: A Randomized Controlled Trial
Study Overview
Detailed Description
After the initial physician consultation and investigations have been completed, the treatment options will be reviewed with the patient. If the patient chooses to proceed with an abdominal myomectomy, then she will be offered participation in the study.
If she chooses to participate, the patient will undergo routine pre-operative assessments including either transvaginal ultrasound or pelvic MRI. The pre-operative hemoglobin level will be measured within at least 2 weeks of the operative procedure.
Randomization to either the vasopressin group or the placebo group will be carried out in the operating room by assigning each recruited patient a consecutively numbered, sealed opaque envelope, which will contain the designated treatment as determined by a computer-generated series of random numbers. The randomization will be performed by an independent member of the division that is not involved in the study.
At the time of induction of anesthesia, a sealed envelope will be opened by the research fellow. At the time of induction of anesthesia, the sealed envelope will be opened to reveal the randomization to only the research fellow. The attending physician will remain blinded. The research fellow will prepare either the placebo solution or the vasopressin and will be responsible for performing the paracervical injection. The attending physician will be responsible for recording the surgeon rate of bleeding, the total ebl, and the total operating time.
In the both groups, one vial (20 units) of vasopressin will be diluted to 40mL with normal saline solution. Not more than 16mL (8units) of vasopressin will be used. This dose was chosen as there is no standard vasopressin dose routinely used. The dose is well below the maximum amount of vasopressin used, and at a level that few complications have been seen in the past.
Given it is standard practice for all patients to receive intramyometrial vasopressin injections, both groups will have the medication ordered and prepared. In the patients randomized to paracervical vasopressin, 8mL (4mL per side of the cervix) will be injected using a 22F spinal needle. An additional 8mL (4 units) will be injected in intramyometrial as this is standard of care in our practice. In the patients randomized to no paracervical vasopressin, 16mL (8 units) will then be used to inject vasopressin intramyometrial prior to the myomectomy. This will help determine if the routine of delivery of vasopressin will aid in decreased blood loss.
The operative case will otherwise proceed in the standard fashion. The total ebl, total operative time, and myomectomy operative time will all be recorded. The myomectomy operative time will be recorded from the time of the first incision on the uterus, to complete closure of any uterine defects.
Study Type
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Ohio
-
Beachwood, Ohio, United States, 44122
- University Hospitals Fertility Center
-
Cleveland, Ohio, United States, 44117
- University Hospitals
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age 18-60 years old
- All women who are candidates for abdominal myomectomy and are willing to accept randomization
Exclusion Criteria:
- Patients unable to consent for the study
- Suspected malignancy
- History of adverse reaction or allergy to vasopressin
- Active cardiovascular or pulmonary disease that would indicate a contraindication to use of vasopressin
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Paracervical & Intramyometrial
Vasopressin will be placed paracervically (8mL, 4 units) and intramyometrial (8mL, 4 units)
|
Either paracervical and intramyometrial or intramyometrial alone at time of abdominal myomectomy.
Other Names:
|
Active Comparator: Intramyometrial
Vasopressin will be placed intramyometrial (16mL, 8 units)
|
Either paracervical and intramyometrial or intramyometrial alone at time of abdominal myomectomy.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
1. Estimating blood loss at the end of myomectomy (calculated as [total suction canister volume] +[laparotomy pads] - [volume of irritation used] - [volume of vasopressin used])
Time Frame: 1 day
|
1 day
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change in Hgb and Hct post-operatively from pre-operative level
Time Frame: 1- 2 days
|
1- 2 days
|
Peri-operative complications
Time Frame: 2 days
|
2 days
|
Total operation time (time from incision to end of surgery)
Time Frame: 1 day
|
1 day
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 043231
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Myoma
-
Tianjin Eye HospitalCompleted
-
Ege UniversityCompleted
-
Seoul National University Bundang HospitalCompleted
-
Kangbuk Samsung HospitalCompletedMyomaKorea, Republic of
-
National Cancer Center, KoreaUnknownGynecologic Cancer | Myoma
-
Yonsei UniversityCompleted
-
Aswan University HospitalUnknown
-
Brugmann University HospitalWithdrawnSymptomatic Submucosal MyomaBelgium, France
-
PregLem SACompletedUterine MyomasCzech Republic, Hungary, India, Romania, Russian Federation, Ukraine
-
Yonsei UniversityCompletedMyoma of UterusKorea, Republic of
Clinical Trials on Vasopressins
-
Endo PharmaceuticalsCompletedHealthy Volunteer Safety StudyUnited States
-
Ascher-Walsh, Charles, M.D.CompletedBlood Loss During Vaginal HysterectomyUnited States
-
Federal University of São PauloFundação de Amparo à Pesquisa do Estado de São PauloCompleted
-
Stanford UniversityCompletedHypotension | Fontan PhysiologyUnited States
-
National Institute of Mental Health and Neuro Sciences...Completed
-
Université de SherbrookeCompleted
-
Yonsei UniversityUnknownUnilateral Ovarian EndometriomaKorea, Republic of
-
University of California, Los AngelesCompleted
-
Stanford UniversityNational Institute of Mental Health (NIMH)Completed
-
University of Electronic Science and Technology...Completed